James Goldman, MD
Ophthalmology · Scottsdale, AZNPI 1528075702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Glaukos Corporation at 29.4% of the total. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $33.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$1K
- AbbVie$976
- Bausch & Lomb, A Division Of Bausch Health US, LLC$373
- Bausch & Lomb Americas Inc.$295
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$500%
- Travel & lodging$8618%
- Food & beverage$9,94791%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 59 | $3,197 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $1,546 |
| Alcon | 30 | $1,033 |
| AbbVie(2 entities) | 42 | $976 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $373 |
| Bausch & Lomb Americas Inc. | 10 | $295 |
| Aerie Pharmaceuticals, Inc. | 14 | $275 |
| Tarsus Pharmaceuticals, Inc. | 8 | $272 |
| Novartis | 13 | $256 |
| Sun Pharmaceutical Industries Inc. | 10 | $230 |
| Dompe US, Inc. | 6 | $195 |
| Rayner Intraocular Lenses Limited | 6 | $178 |
| Mallinckrodt Hospital Products Inc. | 7 | $173 |
| Lensar, Inc. | 2 | $172 |
| Oyster Point Pharma, Inc. | 8 | $153 |
| NEW World Medical,inc. | 13 | $152 |
| Thea Pharma Inc. | 7 | $133 |
| Amgen(2 entities) | 7 | $133 |
| Ivantis, Inc | 2 | $121 |
| Omeros Corporation | 1 | $121 |
| Sight Sciences, Inc. | 2 | $118 |
| Rxsight Inc | 3 | $118 |
| Kala Pharmaceuticals, Inc. | 6 | $109 |
| Eyevance Pharmaceuticals LLC | 7 | $107 |
| Harrow Eye, LLC | 3 | $80 |
| Shire North American Group Inc | 4 | $75 |
| Dutch Ophthalmic, USA | 2 | $53 |
| Carl Zeiss Meditec USA, Inc. | 2 | $53 |
| Notal Vision, Inc. | 2 | $50 |
| Akorn Operating Company LLC | 2 | $33 |
| Astellas Pharma US Inc | 1 | $26 |
| Biotissue Holdings Inc. | 1 | $24 |
| Celularity Inc. | 1 | $18 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$976
- Tecnis Multifocal Family of 1-piece IOLS$976
- Tecnis Symfony IOL$976
- iStent inject W$278
- iDoseTR$233
- DURYSTA$217
- LENSAR LASER SYSTEM$161
- IACCESS$159
- iDose$158
- KXL System$156
- Photrexa$156
- iStent inject Trabecular Micro-Bypass Stent System$148
- IC-8 Apthera IOL$147
- Tecnis Simplicity$144
- XDEMVY$125
- RESTASIS MULTIDOSE$125
- Tecnis IOL$122
- OMIDRIA$121
- Clareon$120
- AcrySof IQ PanOptix UV IOL$119
How this compares
$10,875 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 67 | $80,396 |
| LumiganBimatoprost | 109 | $68,270 |
| MieboPerfluorohexyloctane/Pf | 26 | $22,645 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $10,690 |
| Prednisolone Acetate | 271 | $7,897 |
| Cyclosporine | 20 | $6,386 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,127 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,840 |
| Ketorolac Tromethamine | 227 | $3,663 |
| Loteprednol Etabonate | 13 | $2,229 |
| Travoprost | 18 | $2,196 |
| Brimonidine Tartrate | 11 | $2,126 |
| Ofloxacin | 192 | $1,931 |
| Latanoprost | 124 | $1,503 |
| Difluprednate | 19 | $1,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $976 | $153,793187 claims |
| Bausch & Lomb Americas Inc.Miebo | $295 | $22,64526 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $275 | $10,69022 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $373 | $2,22913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Scottsdale
- Mark BarakatScottsdale$794K
- Kevin TozerScottsdale$32K
- Jay SchwartzScottsdale$30K
- Dharmendra PatelScottsdale$20K
- Paul PetelinScottsdale$20K
- Stephen HwangScottsdale$14K
- Linda TsaiScottsdale$7K
- Steve ChecrounScottsdale$6K
- Sarah MakiScottsdale$6K
- Craig SuiterScottsdale$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.